Morgan & Morgan Announces the Investigation of Furiex Pharmaceuticals, Inc. FURX
NEW YORK, April 28, 2014 /PRNewswire/ -- Morgan & Morgan announces that it is investigating the Board of Directors of Furiex Pharmaceuticals, Inc. ("Furiex" or the "Company") (NASDAQ: FURX) concerning the proposed acquisition by Forex Laboratories, Inc.
If you own shares of Furiex and want more information about the Furiex merger investigation please contact George Pressly, Esq. at 1(800) 631-6234 or email George at AskGeorge@morgansecuritieslaw.com.
Under the terms of the proposal, Furiex shareholders will receive $95.00 in cash for each share of Furiex stock that they own plus a Contingent Value Right worth up to $30.00 for each share they own. The total transaction is valued at approximately $1.5 billion.
Our investigation concerns possible breaches of fiduciary duty and other violations of law by Furiex's Board of Directors for not acting in the best interest of Company's shareholders in connection with the sale process.
Morgan & Morgan is one of the nation's largest 200 law firms. In addition to securities fraud, the firm also practices in the areas of antitrust, personal injury, consumer protection, overtime, and product liability. All of the Firm's legal endeavors are rooted in its core mission: provide investor and consumer protection and always fight "for the people."
Attorney advertising. Prior results do not guarantee a similar outcome.
Morgan & Morgan
Peter Safirstein, Esq.
28 West 44th Street
New York, NY 10036
SOURCE Morgan & Morgan